{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T19:33:23Z","timestamp":1771788803096,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.critrevonc.2024.104321","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T08:35:05Z","timestamp":1709800505000},"page":"104321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Efficacy of immune checkpoint inhibitors combinations as first-line systemic treatment in patients with advanced urothelial carcinoma: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"196","author":[{"given":"Fernando Sabino Marques","family":"Monteiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrey","family":"Soares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Mollica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caio Abner","family":"Leite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre Paterno Castello Dias","family":"Carneiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria T.","family":"Bourlon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre Deeke","family":"Sasse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shilpa","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Massari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.critrevonc.2024.104321_bib1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann. Intern Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104321_bib2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.urolonc.2021.10.002","article-title":"The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer","volume":"41","author":"Atiq","year":"2023","journal-title":"Urol. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104321_bib3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/annonc\/mdx692","article-title":"Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a retrospective international study of invasive\/advanced cancer of the urothelium (RISC)","volume":"29","author":"Bamias","year":"2018","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104321_bib4","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1200\/JCO.2011.38.6979","article-title":"Randomized phase III study comparing paclitaxel\/cisplatin\/gemcitabine and gemcitabine\/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987","volume":"30","author":"Bellmunt","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104321_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejcsup.2016.01.001","article-title":"Urothelial carcinoma management in elderly or unfit patients","volume":"14","author":"Bellmunt","year":"2016","journal-title":"EJC Suppl."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104321_bib6","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/1759-7714.13867","article-title":"Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: a systematic review and meta-analysis","volume":"12","author":"Brito","year":"2021","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104321_bib7","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3389\/fimmu.2020.01088","article-title":"Looking for the optimal PD-1\/PD-L1 inhibitor in cancer treatment: a comparison in basic structure, function, and clinical practice","volume":"11","author":"Chen","year":"2020","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104321_bib8","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cncr.22031","article-title":"Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder","volume":"107","author":"Dash","year":"2006","journal-title":"Cancer"},{"issue":"19","key":"10.1016\/j.critrevonc.2024.104321_bib9","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus Gemcitabine\u2013Cisplatin in Advanced Urothelial Carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.critrevonc.2024.104321_bib10","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104321_bib11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamaoncol.2019.5367","article-title":"Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis","volume":"6","author":"Duan","year":"2020","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104321_bib12","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.clgc.2023.05.017","article-title":"Predictors of efficacy of immune checkpoint inhibitors in patients with advanced urothelial carcinoma: a systematic review and meta-analysis","volume":"21","author":"Ferro","year":"2023","journal-title":"Clin. Genitourin. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104321_bib13","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.clgc.2023.05.017","article-title":"Predictors of efficacy of immune checkpoint inhibitors in patients with advanced urothelial carcinoma: a systematic review and meta-analysis","volume":"21","author":"Ferro","year":"2023","journal-title":"Clin. Genitourin. Cancer"},{"issue":"10236","key":"10.1016\/j.critrevonc.2024.104321_bib14","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2024.104321_bib15","doi-asserted-by":"crossref","first-page":"S682","DOI":"10.1016\/j.annonc.2021.08.054","article-title":"658MO Cisplatin (cis)-related immunomodulation and efficacy with atezolizumab (atezo) + cis- vs carboplatin (carbo)-based chemotherapy (chemo) in metastatic urothelial cancer (mUC)","volume":"32","author":"Galsky","year":"2021","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104321_bib16","doi-asserted-by":"crossref","first-page":"195.e1","DOI":"10.1016\/j.urolonc.2021.11.014","article-title":"Real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States","volume":"40","author":"Geynisman","year":"2022","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104321_bib17","article-title":"Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study","author":"Grande","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104321_bib18","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.humpath.2020.10.006","article-title":"Human epidermal growth factor receptor 2 overexpression is frequently discordant between primary and metastatic urothelial carcinoma and is associated with intratumoral human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Grigg","year":"2021","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.critrevonc.2024.104321_bib19","series-title":"Cochrane Hand-book for Systematic Reviews of Interventions","author":"Higgins JPT","year":"2019"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104321_bib20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","article-title":"Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices: part 2","volume":"14","author":"Hoaglin","year":"2011","journal-title":"Value Health"},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104321_bib21","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/oncolo\/oyac140","article-title":"Clinical features, survival, and burden of toxicities in survivors more than one year after lung cancer immunotherapy","volume":"27","author":"Hsu","year":"2022","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104321_bib22","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3390\/ijms23031133","article-title":"Novel therapeutic opportunities in neoadjuvant setting in urothelial cancers: a new horizon opened by molecular classification and immune checkpoint inhibitors","volume":"23","author":"Iacovino","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104321_bib23","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/cncr.32645","article-title":"Impact of performance status on treatment outcomes: a real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors","volume":"126","author":"Khaki","year":"2020","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104321_bib24","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance","volume":"29","author":"Kl\u00fcmper","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104321_bib25","first-page":"75.e1","article-title":"Clinicopathological characteristics, prognosis, and chemosensitivity in patients with metastatic upper tract urothelial carcinoma","volume":"39","author":"Li","year":"2021","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"issue":"16_Supplement","key":"10.1016\/j.critrevonc.2024.104321_bib26","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2020-5581","article-title":"Abstract 5581: Enfortumab vedotin, an anti-Nectin-4 ADC demonstrates bystander cell killing and immunogenic cell death anti-tumor activity mechanisms of action in urothelial cancers","volume":"80","author":"Liu","year":"2020","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104321_bib27","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.1992.10.7.1066","article-title":"A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study","volume":"10","author":"Loehrer","year":"1992","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2024.104321_bib28","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.critrevonc.2024.104321_bib29","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat. Med."},{"key":"10.1016\/j.critrevonc.2024.104321_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102395","article-title":"Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives","volume":"106","author":"Nicol\u00f2","year":"2022","journal-title":"Cancer Treat. Rev."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104321_bib31","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/jrsm.1373","article-title":"MetaInsight: an interactive web-based tool for analyzing, interrogating, and visualizing network meta-analyses using R-shiny and netmeta","volume":"10","author":"Owen","year":"2019","journal-title":"Res. Synth. Methods"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104321_bib32","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.urolonc.2022.07.006","article-title":"Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: a scoping review","volume":"40","author":"Padua","year":"2022","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104321_bib33","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104321_bib34","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2024.104321_bib35","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104321_bib36","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104321_bib37","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann. Oncol."},{"issue":"19","key":"10.1016\/j.critrevonc.2024.104321_bib38","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN bladder 100 trial after \u22652 years of follow-up","volume":"41","author":"Powles","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104321_bib39","doi-asserted-by":"crossref","first-page":"S1340","DOI":"10.1016\/j.annonc.2023.10.106","article-title":"LBA6 EV-302\/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la\/mUC)","volume":"34","author":"Powles","year":"2023","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104321_bib40","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.euf.2021.01.003","article-title":"Expression of programmed cell death ligand 1 as a predictive biomarker in metastatic urothelial carcinoma patients treated with first-line immune checkpoint inhibitors versus chemotherapy: a systematic review and meta-analysis","volume":"8","author":"Rizzo","year":"2022","journal-title":"Eur. Urol. Focus"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104321_bib41","first-page":"540","article-title":"Comprehensive molecular characterization of muscle-invasive bladder","volume":"171","author":"Robertson","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104321_bib42","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1038\/s41467-019-10873-y","article-title":"Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling","volume":"10","author":"Robinson","year":"2019","journal-title":"Nat. Commun."},{"issue":"33","key":"10.1016\/j.critrevonc.2024.104321_bib43","doi-asserted-by":"crossref","first-page":"5634","DOI":"10.1200\/JCO.2008.21.4924","article-title":"Randomized phase II\/III trial assessing Gemcitabine\/ Carboplatin and Methotrexate\/Carboplatin\/Vinblastine in patients with advanced urothelial cancer \u201cUnfit\u201d for Cisplatin-based chemotherapy: Phase II\u2014results of EORTC study 30986","volume":"27","author":"Santis","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104321_bib44","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.annonc.2023.10.003","article-title":"Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial","volume":"35","author":"Siefker-Radtke","year":"2024","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104321_bib45","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104321_bib46","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejca.2005.08.032","article-title":"Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours","volume":"42","author":"Sternberg","year":"2006","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104321_bib47","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of Incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"17","key":"10.1016\/j.critrevonc.2024.104321_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174341","article-title":"Efficacy of immune checkpoint inhibitors in upper tract urothelial carcinomas: current knowledge and future directions","volume":"13","author":"Thouvenin","year":"2021","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104321_bib49","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824000647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824000647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T17:41:17Z","timestamp":1715449277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824000647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":49,"alternative-id":["S1040842824000647"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104321","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of immune checkpoint inhibitors combinations as first-line systemic treatment in patients with advanced urothelial carcinoma: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104321","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104321"}}